Condition
Juvenile Dermatomyositis clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Juvenile Dermatomyositis clinical trials that are recruiting, at sites in 5 countries (most in United States (4), China (1), Germany (1)). By phase: Phase 1 (1), Phase 2/3 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Juvenile Dermatomyositis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Patient-rooted insights to shape myositis science | — | New Orleans, Louisiana | Recruiting | Jan 28, 2026 |
| Descartes-08 treatment for children, teens, and young adults with select autoimmune diseases | Phase 1/2 | Washington D.C., District of Columbia and 2 other locations | Recruiting | Jul 28, 2025 |
| CD19-targeted CAR-T therapy for treating refractory juvenile dermatomyositis | Phase 1 | Hangzhou, Zhejiang | Recruiting | Aug 26, 2024 |
| Evaluating CABA-201 for treating active idiopathic inflammatory myopathy | Phase 2/3 | Orange, California and 37 other locations | Recruiting | Dec 4, 2023 |
| Investigating environmental factors linked to anti-synthetase syndrome | — | Miami, Florida and 7 other locations | Recruiting | Jan 13, 2011 |
All recruiting trials (5)
-
Patient-rooted insights to shape myositis science
This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.
-
Descartes-08 treatment for children, teens, and young adults with select autoimmune diseases
This trial will test whether Descartes-08 is safe and can help control disease in children, adolescents, and young adults with childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, or juvenile dermatomyositis.
-
CD19-targeted CAR-T therapy for treating refractory juvenile dermatomyositis
This study is testing a new CAR-T therapy for children with tough-to-treat juvenile dermatomyositis to see if it can help improve their condition.
-
Evaluating CABA-201 for treating active idiopathic inflammatory myopathy
This study is testing a new cell therapy called CABA-201 to see if it can help people with active idiopathic inflammatory myopathy feel better by reducing muscle inflammation and weakness.
-
Investigating environmental factors linked to anti-synthetase syndrome
This study is trying to see if certain environmental factors, like infections or other triggers, might play a role in causing anti-synthetase syndrome in people with myositis.
Related topics
Quick answers
How many Juvenile Dermatomyositis clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in United States (4 trials), China (1 trial), Germany (1 trial), Italy (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 2/3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.